drugset / Trial / NCT05632926
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)
Non-randomizedSequentialOpen-labelTreatment
Summary
The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study to assess the efficacy and safety of CBL-514 in participants with Edematous Fibrosclerotic Panniculopathy (EFP) cellulite.
Timeline
- Start
- 2023-01-09
- Primary completion
- 2023-05-03
- Completion
- 2023-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBL-514 | Unknown | 40 mg | Subcutaneous |
| Subject | CBL-514 | Unknown | 60 mg | Subcutaneous |
| Subject | CBL-514 | Unknown | 80 mg | Subcutaneous |